Ruxolitinib inhibits normal erythropoietin and thrombopoietin signaling through JAK2 (through the erythropoietin and thrombopoietin receptors, respectively) [6], often resulting in dose-dependent anemia and thrombocytopenia [21, 61]. Here, EPO is linked to anemia (phenotype).